LONDON--(BUSINESS WIRE)--Increasing prevalence of obesity has resulted in the growth of the Global Anti-Obesity Drugs Market, which is expected to post a CAGR of 39.43 percent from 2015-2019, says research firm TechNavio.
Growing rates of obesity worldwide are offering huge opportunities for drug manufacturing companies to develop and manufacture highly effective drugs.
About the Report
The latest report by TechNavio highlights fierce competition among vendors as a major factor driving market growth.
New pipeline drugs developed by vendors should display efficacy and safety profiles that surpass options currently on the market.
“Competition in the market is expected to intensify with the entry of new drugs during the forecast period,” says Faisal Ghaus, Vice President of TechNavio.
“The landscape is vast, with competitors ranging from Arena Pharmaceuticals and Orexigen Therapeutics to big pharmaceutical companies, gearing up to make better, more effective anti-obesity drugs with fewer side effects.”
Anti-obesity drugs currently available on the market come with a list of troubling side effects. Any product offerings that are safe for long-term use will likely have a positive impact on market growth through to 2019.
TechNavio currently has more than 3000 market research reports on a huge range of topics, including:
TechNavio is a leading global technology research and advisory company.
Founded in 2003, TechNavio has about 200 analysts globally and develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries.
TechNavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.